What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials

In phase II studies with CUP patients, BORR and the threshold of BORR > 30% for defining promising drug appears adequate.